NASDAQ$NKTX
Nkarta Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Nkarta reported positive preliminary data from NKX101 and NKX019 Phase 1 studies and raised additional capital.
Nkarta reported financial results for the second quarter ended June 30, 2022. The company announced positive preliminary data for its co-lead NK cell therapy candidates, NKX101 and NKX019, and raised additional capital for advancing these programs.
- Reported positive preliminary data from NKX101 Phase 1 study in patients with relapsed / refractory AML and NKX019 Phase 1 study in patients with relapsed / refractory NHL, validating the company’s platform for engineered CAR NK cell therapy candidates.
- Additional NKX101 and NKX019 clinical data expected by year-end 2022, including safety and activity data for newly enrolled patients at higher dose monotherapy regimen and extended durability follow-up for previously reported patient responses.
- Nkarta plans to present additional clinical data in the second half of 2022 from its ongoing dose escalation monotherapy clinical trials of NKX101 and NKX019.
- In April 2022, Nkarta received approximately $215.6 million in net proceeds from a public offering of its common stock.
Headline financials
Revenue & EPS history
Nkarta · Revenue · Quarterly
$0
Forward guidance
Nkarta expects its current cash and cash equivalents will be sufficient to fund its current operating plan into 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2022
+0.9%
Avg return
Earnings day
-2.2%
Avg return
5 days after
-0.9%
Avg return
30 days after
63%
15 / 24 earnings
Positive
+16.2%
Q4 2021
Best reaction
-30.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.9% | -14.8% | — | |
| Q1 2026 | +3.5% | -16.1% | -13.2% | |
| Q3 2025 | +3.1% | -4.6% | -4.6% | |
| Q2 2025 | +12.8% | +19.9% | +0.5% | |
| Q1 2025 | +1.2% | -0.6% | -4.6% | |
| Q4 2024 | +3.2% | -15.4% | +13.3% | |
| Q3 2024 | -4.8% | -9.0% | -23.0% | |
| Q2 2024 | +1.2% | +0.0% | +10.3% | |
| Q1 2024 | -2.3% | +2.3% | +3.1% | |
| Q4 2023 | -30.3% | -22.8% | -43.0% | |
| Q3 2023 | -5.6% | +7.0% | +27.0% | |
| Q2 2023 | -0.5% | -1.0% | -20.5% | |
| Q1 2023 | -4.1% | -4.1% | -0.9% | |
| Q4 2022 | +1.3% | -7.1% | +19.3% | |
| Q3 2022 | -8.4% | -2.1% | -35.5% | |
| Q2 2022 | +8.8% | +11.1% | -8.5% | |
| Q1 2022 | +12.8% | +11.1% | +6.9% | |
| Q4 2021 | +16.2% | +6.2% | -15.2% | |
| Q3 2021 | +7.7% | +7.2% | -15.0% | |
| Q2 2021 | -1.9% | -5.0% | -29.0% | |
| Q4 2020 | +0.0% | -14.4% | -30.3% | |
| Q3 2020 | +2.9% | +14.5% | +122.0% | |
| Q2 2020 | -7.0% | -12.0% | +21.1% | |
| Q1 2021 | +11.3% | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro